Date: 2015-03-04
Type of information: Licensing agreement
Compound: poziotinib (HM781-36B)
Company: Spectrum Pharmaceuticals (USA - NV) Hanmi Pharmaceuticals (South Korea)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism: tyrosine kinase inhibitor. Poziotinib (HM781-36B) is a novel, oral, quinazoline-based pan-HER inhibitor that irreversibly blocks signaling through the HER family of tyrosine-kinase receptors including HER1 (erbB1; EGFR), HER2 (erbB2), and HER4 (erbB4), as well as HER receptor mutations; this, in turn, leads to inhibition of the proliferation of tumor cells that overexpress these receptors. Mutations or overexpression/amplification of HER family receptors have been associated with a number of different cancers, including non-small cell lung cancer (NSCLC), breast cancer, gastric cancer, etc.
Disease:
Details: * On March 4, 2015, Spectrum Pharmaceutical, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced it has entered into a licensing agreement with Hanmi Pharmaceuticals for poziotinib, a drug being investigated for the treatment of cancer. Currently, poziotinib is being investigated by Hanmi in EGFR-mutant NSCLC (Phase 2, sponsored by National OncoVenture), gastric cancer (Phase 2), head & neck cancer (Phase 2) and HER2 positive breast cancer (Phase 2, sponsored by National OncoVenture, a funding initiative by the Korean government's National Cancer Center).Under the terms of the agreement, Spectrum received exclusive license to develop, manufacture and commercialize worldwide excluding Korea and China. Hanmi shall remain responsible for the cost of the ongoing Phase 2 studies through completion.
Financial terms:
Latest news:
